Skip to content

(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE

(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) Correlate With Depression and Anxiety in Systemic Lupus Erythematosus Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06255743
Enrollment
50
Registered
2024-02-13
Start date
2024-02-14
Completion date
2025-02-14
Last updated
2024-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Keywords

Depression -Anxiety-Anti-Ribosomal P Protein Antibody - Anti-U1 Antibody - Anti-Nucleosome Antibody - Anti-Double Strad DNA Antibody

Brief summary

the study determine the relation between the degree of (Depression and Anxiety) in Systemic Lupus Erythematosus Patients by zung self rating depression scale and zung self rating anxiety scale and (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies).

Interventions

DIAGNOSTIC_TESTAnti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies

determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who fulfill the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria or 2019 American College of Rheumatology/European League against Rheumatism classification criteria of Systemic Lupus Erythematosus. 2. Patients who is able to give informed consent to join the study.

Exclusion criteria

* \- Any patient with any autoimmune disease other than systemic lupus erythematosus.

Design outcomes

Primary

MeasureTime frameDescription
the degree of depression1 yearby using zung self-rating depression scale
the degree of anxiety1 yearby using zung self-rating anxiety scale

Secondary

MeasureTime frameDescription
Anti-Ribosomal P Protein antibody1 yearwas examined by ANA profile by immunoblot based assay with which the plasma of heparin-anticoagulated venous blood and there of IgG antibodies reacted against the auto-antigens are tested.
Anti-U1 RNP antibody1 yearwas examined by ANA profile by immunoblot based assay with which the plasma of heparin-anticoagulated venous blood and there of IgG antibodies reacted against the auto-antigens are tested.
Anti-Nucleosome antibody1 yearwas examined by ANA profile by immunoblot based assay with which the plasma of heparin-anticoagulated venous blood and there of IgG antibodies reacted against the auto-antigens are tested.
Anti-Double Strad DNA Antibody1 yearwas examined by ANA profile by immunoblot based assay with which the plasma of heparin-anticoagulated venous blood and there of IgG antibodies reacted against the auto-antigens are tested.

Countries

Egypt

Contacts

Primary ContactOsama S Daif Allah, Assistant Professor
hebamaher1919@gmail.com01006425746
Backup ContactHeba M Kamaly, Assistant lecture
hebamaher1919@gmail.com01093128552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026